Muhammet Li̇mon, Dilek Tezcan, Semral Gülcemal, Sema Yilmaz
{"title":"Anca İlişkili Vaskülitlerde Tek Merkez Deneyimi","authors":"Muhammet Li̇mon, Dilek Tezcan, Semral Gülcemal, Sema Yilmaz","doi":"10.15321/geneltipder.2021.305","DOIUrl":null,"url":null,"abstract":"Introduction: Granulomatosis polyangitiis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA and microscopic polyangiitis(MPA) are small vessel vasculitides associated with anti-neutrophil cytoplasmic antibody (ANCA). İn this study, the frequency of ANCA associated vasculitis and treatment responses in our clinic are evaluated. Methods: This retrospective study was performed between January 2015- December 2018. 18 patients who older than 18 and diagnosed ANCA associated vasculitis according to the 2012 Chapel Hill Classification were included. Results: İn totals, 18 patients who diagnosed ANCA associated vasculitis were included, 12 of whom females, 6 of whom males. The mean age of the patients was 57.8. Two of the patients were diagnosed with EGPA, 3 with MPA and 13 with GPA. 11 of the patients followed up with GPA with systemic involvement and 2 with limited involvement. The most common involvement in patients with GPA was pulmonary involvement with 76% and renal involvement in 53% of the patients. Pulmonary involvement was detected in 2 patients and lung involvement in 2 patients in MPA. Pulmonary involvement was observed in 2 patients with EGPA. RF and ANA positivity was highest in GPA. İt was observed in combination with pulse steroid and cyclophosphamide in the induction treatment of ANCA-associated vasculitis. It was seen that 3 GPA patients had recurrence and followed up with rituximab. Discussion-conclusion: ANCA related vasculitides treatment and clinic are similar. İn the treatment of ANCA-associated vasculitis, remission should be achie- ved in a short time. In recurrent cases, rituximab may be preferred.","PeriodicalId":139503,"journal":{"name":"Genel Tip Dergisi","volume":"23 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genel Tip Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15321/geneltipder.2021.305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Granulomatosis polyangitiis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA and microscopic polyangiitis(MPA) are small vessel vasculitides associated with anti-neutrophil cytoplasmic antibody (ANCA). İn this study, the frequency of ANCA associated vasculitis and treatment responses in our clinic are evaluated. Methods: This retrospective study was performed between January 2015- December 2018. 18 patients who older than 18 and diagnosed ANCA associated vasculitis according to the 2012 Chapel Hill Classification were included. Results: İn totals, 18 patients who diagnosed ANCA associated vasculitis were included, 12 of whom females, 6 of whom males. The mean age of the patients was 57.8. Two of the patients were diagnosed with EGPA, 3 with MPA and 13 with GPA. 11 of the patients followed up with GPA with systemic involvement and 2 with limited involvement. The most common involvement in patients with GPA was pulmonary involvement with 76% and renal involvement in 53% of the patients. Pulmonary involvement was detected in 2 patients and lung involvement in 2 patients in MPA. Pulmonary involvement was observed in 2 patients with EGPA. RF and ANA positivity was highest in GPA. İt was observed in combination with pulse steroid and cyclophosphamide in the induction treatment of ANCA-associated vasculitis. It was seen that 3 GPA patients had recurrence and followed up with rituximab. Discussion-conclusion: ANCA related vasculitides treatment and clinic are similar. İn the treatment of ANCA-associated vasculitis, remission should be achie- ved in a short time. In recurrent cases, rituximab may be preferred.